基质金属蛋白酶-9在子宫内膜癌中过表达的临床意义：一项遵循PRISMA规范的荟萃分析。
Clinical significance of MMP-9 overexpression in endometrial cancer: A PRISMA-compliant meta-analysis.
作者信息
Li Xia, Zha Li, Li Bo, Sun Rong, Liu Jianhua, Zeng Hongwei
机构信息
Department of Critical Medicine, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Department of Gynaecology and Obstetrics, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
出版信息
Front Oncol. 2022 Oct 26;12:925424. doi: 10.3389/fonc.2022.925424. eCollection 2022.
OBJECTIVE
Several studies have found that MMP-9, one of the extracellular matrix-degrading proteinases, was involved in EC's (endometrial cancer) clinical progression and prognosis. However, the results involving the associations of MMP-9 expression with risk, clinical features and prognosis of EC were conflicting. Therefore, we performed a systematic review and meta-analysis to clarify the correlation of MMP-9 expression with EC.
METHODS
Relative studies involving the associations between MMP-9 expression and EC were retrieved from PubMed, Embase, Web of Science and CNKI (China National Knowledge Infrastructure) electronic databases. OR (odds ratio) with 95% CI (confidence interval) was applied to evaluate the associations of MMP-9 expression with risk and clinical features of EC. Furthermore, we evaluated the role of MMP-9 expression in prognosis of EC using HR and 95% CI. The funnel plots and Begg test were used to assess the publication bias.
RESULTS
A total of 28 eligible studies were acquired from Pubmed, Embase, Web of science and CNKI databases. We found MMP-9 overexpression was significantly associated with the risk of EC (OR = 11.02, 95% CI = 7.51-16.16, < 0.05). In the meantime, MMP-9 overexpression was significantly associated with the tumor grade, FIGO stage, lymph node metastasis and myometrial invasion (Tumor grade: OR = 1.68, 95% CI = 1.09-2.58, < 0.05; FIGO stage: OR = 3.25, 95% CI = 1.73-6.08, < 0.05; Lymph node metastasis: OR = 2.98, 95% CI = 1.27-7.03, < 0.05; Myometrial invasion: OR = 2.42, 95% CI = 1.42-4.12, < 0.05) in Asians. In addition, the overall results showed that MMP-9 overexpression predicted a worse prognosis of EC (OR = 1.82, 95% CI = 1.01-2.62, < 0.05).
CONCLUSIONS
MMP-9 overexpression might be a potential predictor of poor clinical progression and prognosis of EC.
目的
多项研究发现，细胞外基质降解蛋白酶之一的基质金属蛋白酶-9（MMP-9）参与了子宫内膜癌（EC）的临床进展和预后。然而，关于MMP-9表达与EC风险、临床特征及预后之间关联的研究结果相互矛盾。因此，我们进行了一项系统评价和荟萃分析，以阐明MMP-9表达与EC的相关性。
方法
从PubMed、Embase、Web of Science和中国知网（CNKI）电子数据库中检索有关MMP-9表达与EC之间关联的相关研究。应用比值比（OR）及95%置信区间（CI）评估MMP-9表达与EC风险及临床特征的关联。此外，我们使用风险比（HR）及95%CI评估MMP-9表达在EC预后中的作用。采用漏斗图和Begg检验评估发表偏倚。
结果
从PubMed、Embase、Web of Science和CNKI数据库共获取28项符合条件的研究。我们发现MMP-9过表达与EC风险显著相关（OR = 11.02，95%CI = 7.51 - 16.16，P < 0.05）。同时，在亚洲人中，MMP-9过表达与肿瘤分级、国际妇产科联盟（FIGO）分期、淋巴结转移及肌层浸润显著相关（肿瘤分级：OR = 1.68，95%CI = 1.09 - 2.58，P < 0.05；FIGO分期：OR = 3.25，95%CI = 1.73 - 6.08，P < 0.05；淋巴结转移：OR = 2.98，95%CI = 1.27 - 7.03，P < 0.05；肌层浸润：OR = 2.42，95%CI = 1.42 - 4.12，P < 0.05）。此外，总体结果显示MMP-9过表达预示着EC预后较差（OR = 1.82，95%CI = 1.01 - 2.62，P < 0.05）。
结论
MMP-9过表达可能是EC临床进展不良及预后不佳的潜在预测指标。
Zotero 插件